Biopharma Company Working On Synthetic THC Drug To Treat Anxiety Launches NASDAQ IPO
Portfolio Pulse from Nina Zdinjak
Pre-clinical-stage biopharma company, MIRA Pharmaceuticals, has launched its initial public offering on NASDAQ. The company is developing a synthetic THC prescription drug, MIRA1a, to treat anxiety, pain, and cognition disorders without the side effects of cannabis or opioids. If approved by the FDA, MIRA1a could advance the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders.
August 04, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MIRA Pharmaceuticals has launched its IPO on NASDAQ. The company's lead drug candidate, MIRA1a, if approved, could revolutionize the treatment of various disorders.
The launch of MIRA's IPO on NASDAQ is a significant milestone for the company. The development of MIRA1a, a synthetic THC drug, could potentially revolutionize the treatment of anxiety, pain, and cognition disorders. This could significantly increase the company's market value if the drug is approved by the FDA.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100